Octagon Capital Advisors »

Ocular Therapeutix shares owned by Octagon Capital Advisors

Quarter-by-quarter ownership of Ocular Therapeutix (OCUL) shares owned by Octagon Capital Advisors from 13F filings

Historical chart of Octagon Capital Advisors investment in Ocular Therapeutix

Tip: Access up to 7 years of quarterly data

All positions including Ocular Therapeutix held by Octagon Capital Advisors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Ocular Therapeutix by Octagon Capital Advisors

Quarter filed Position value Share count Share price at filing
2024-03-31 $22M 2.4M 9.10

More positions owned by Octagon Capital Advisors

Apellis Pharmaceuticals Call Option (APLS)
Alpine Immune Sciences (ALPN)
Dianthus Therapeutics (DNTH)
Verona Pharma Sponsored Ads (VRNA)
Dyne Therapeutics (DYN)
Arrivent Biopharma
Insmed Com Par $.01 (INSM)
Centessa Pharmaceuticals Sponsored Ads (CNTA)
Eyepoint Pharmaceuticals Com New (EYPT)
Ocular Therapeutix (OCUL)
Structure Therapeutics Sponsored Ads (GPCR)
Bridgebio Pharma (BBIO)
Mind Medicine Mindmed Com New (MNMD)
IsoRay (CATX)
Corbus Pharmaceuticals Hldgs Com New (CRBP)

View all positions for Octagon Capital Advisors

Top funds holding Ocular Therapeutix

Summer Road
VR Adviser
BlackRock
Vanguard Group
Opaleye Management
Logos Global Management
Citadel Advisors
Perceptive Advisors
Geode Capital Management
Octagon Capital Advisors
Deltec Asset Management
Franklin Resources
Dr. Jeffrey R. Jay, M.D.
Morgan Stanley
Nuveen Asset Management

View all funds holding Ocular Therapeutix